Health Care FinancePart D/Prescription Drugs

Gilead to launch generic version of its controversially priced hepatitis C drugs

(By Alia Paavola for Becker’s Hospital Review)

Gilead Sciences will offer a cheaper version of its blockbuster hepatitis C drugs, Epclusa and Harvoni, which sparked controversy when they were initially introduced at a price of more than $1,000 per pill, according to Bloomberg. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or



Leave a Reply